Chapter: Pharmacology of Pethidine

1. Introduction/Overview

Pethidine, also known internationally as meperidine, is a synthetic opioid analgesic with a significant historical role in pain management. First synthesized in 1939, it represented one of the earliest fully synthetic opioids and was initially investigated for its anticholinergic properties before its potent analgesic effects were recognized. For decades, pethidine occupied a central position in the treatment of moderate to severe pain, particularly in perioperative and obstetric settings. Its clinical use has undergone substantial reevaluation in contemporary practice due to a growing understanding of its unique pharmacokinetic profile and metabolite-associated toxicities.

The clinical relevance of pethidine persists, though its applications have become more restricted. It remains a subject of essential study for medical and pharmacy students as a prototypical phenylpiperidine opioid, offering insights into opioid pharmacology, the consequences of active metabolite accumulation, and the evolution of therapeutic guidelines based on pharmacovigilance. Knowledge of pethidine is crucial not only for its selective modern uses but also for managing patients with a history of exposure to the drug and for understanding the principles governing the safe use of opioids with neurotoxic metabolites.

Learning Objectives

• Describe the chemical classification of pethidine and its relationship to other opioid analgesics.
• Explain the dual mechanism of action involving opioid receptor agonism and ancillary pharmacodynamic effects.
• Analyze the pharmacokinetic profile of pethidine, with emphasis on the formation, activity, and toxicity of its primary metabolite, norpethidine.
• Evaluate the approved therapeutic indications, contraindications, and the rationale for its restricted use in modern formularies.
• Identify the major adverse effects, drug interactions, and special population considerations essential for safe clinical application.

2. Classification

Pethidine is systematically classified within multiple hierarchical frameworks relevant to pharmacology and therapeutics.

2.1. Therapeutic and Pharmacological Classification

The primary classification places pethidine among opioid analgesics. More specifically, it is categorized as a strong agonist at the mu-opioid receptor (MOR), aligning it pharmacologically with morphine, fentanyl, and hydromorphone in its capacity to relieve severe pain. Therapeutically, it belongs to the class of drugs used for the management of moderate to severe acute pain.

2.2. Chemical Classification

Chemically, pethidine is a member of the phenylpiperidine class of synthetic opioids. Its structure, 1-methyl-4-phenyl-4-piperidine carboxylic acid ethyl ester, distinguishes it from the phenanthrene derivatives like morphine and codeine. This phenylpiperidine backbone is shared by other agents such as fentanyl, sufentanil, and loperamide, though significant variations in the side chains confer differences in potency, lipid solubility, and receptor binding kinetics. Pethidine is an ester derivative, a feature relevant to its metabolism.

2.3. Legal and Regulatory Classification

In most jurisdictions, pethidine is classified as a Schedule II controlled substance under international drug treaties and national regulations, such as the Controlled Substances Act in the United States. This designation indicates a high potential for abuse and dependence, alongside an accepted medical use. Its prescription and dispensing are subject to stringent regulatory controls.

3. Mechanism of Action

The analgesic and secondary effects of pethidine are mediated through a primary opioid mechanism, supplemented by notable non-opioid pharmacodynamic actions.

3.1. Primary Opioid Receptor Agonism

Pethidine functions predominantly as an agonist at the mu-opioid receptor (MOR). Binding to this G-protein coupled receptor, primarily within the central nervous system (CNS), initiates a cascade of intracellular events. Agonism inhibits adenylate cyclase, reduces cyclic adenosine monophosphate (cAMP) production, and promotes the opening of potassium channels while inhibiting voltage-gated calcium channels. The net effect is neuronal hyperpolarization and a reduction in the presynaptic release of excitatory neurotransmitters, such as substance P. This attenuates nociceptive signal transmission in pathways involving the dorsal horn of the spinal cord, thalamus, and limbic system, resulting in analgesia. The affinity and intrinsic activity of pethidine at the mu receptor are less than those of morphine, contributing to its lower relative analgesic potency.

3.2. Secondary Pharmacodynamic Effects

Unlike pure opioid agonists, pethidine exhibits ancillary properties that influence its clinical profile.

• Local Anesthetic Effects: Pethidine possesses structural features that confer sodium channel-blocking activity. When administered neuraxially (e.g., epidurally), it can produce sensory and motor blockade, a characteristic not shared by morphine. This action is independent of its opioid receptor activity.
• Anticholinergic (Atropine-like) Effects: The chemical structure of pethidine confers mild antimuscarinic activity. This may contribute to a lower incidence of biliary spasm compared to equianalgesic doses of morphine and can also manifest as tachycardia, dry mouth, and reduced gastrointestinal motility. However, the latter effect is overwhelmingly dominated by its opioid action on enteric neurons.
• Serotonergic Effects: Pethidine has been shown to inhibit neuronal reuptake of serotonin. This property is considered a key factor in its potential to precipitate the serotonin syndrome, particularly when co-administered with other serotonergic agents like monoamine oxidase inhibitors (MAOIs) or selective serotonin reuptake inhibitors (SSRIs).

3.3. Cellular and Molecular Consequences

Activation of mu-opioid receptors in various CNS loci underlies both therapeutic and adverse effects. Supraspinal analgesia and euphoria are mediated by receptors in the periaqueductal gray and limbic system. Respiratory depression results from agonist action on brainstem respiratory centers, particularly the pre-Bötzinger complex. Sedation involves the thalamus and cortex. Activation of receptors in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema leads to reduced motility and nausea, respectively. The metabolite, norpethidine, is a weaker mu agonist but a more potent convulsant, primarily through non-opioid mechanisms that may involve reduced seizure threshold and possible N-methyl-D-aspartate (NMDA) receptor antagonism.

4. Pharmacokinetics

The pharmacokinetic profile of pethidine is characterized by significant first-pass metabolism, active metabolite formation, and variability influenced by patient factors.

4.1. Absorption

Pethidine is well absorbed from the gastrointestinal tract and from parenteral sites. Oral bioavailability is approximately 50% due to significant first-pass hepatic metabolism. Following intramuscular (IM) injection, absorption is generally rapid and complete, with peak plasma concentrations (C_max) achieved within 30 to 60 minutes. Subcutaneous administration provides similar absorption kinetics. Onset of analgesic action occurs within 10 minutes after intravenous (IV) administration, 10-15 minutes after IM injection, and 30-60 minutes after oral ingestion.

4.2. Distribution

Pethidine is a moderately lipid-soluble drug with a volume of distribution (V_d) ranging from 3 to 5 L/kg, indicating extensive distribution into tissues. It readily crosses the blood-brain barrier and the placenta. Plasma protein binding is moderate, primarily to alpha-1-acid glycoprotein and albumin, with an estimated bound fraction of 60-70%. The distribution phase is rapid, contributing to its quick onset of action.

4.3. Metabolism

Hepatic metabolism is the principal route of pethidine elimination and is the source of its most critical pharmacokinetic challenge. Metabolism occurs primarily via two pathways:

1. N-demethylation: Catalyzed by the cytochrome P450 enzyme CYP3A4 (and to a lesser extent CYP2B6), this pathway produces the primary metabolite, norpethidine (normeperidine). Norpethidine is pharmacologically active, possessing analgesic properties but, more importantly, significant neurotoxic and convulsant potential. Its elimination half-life is 15-40 hours, substantially longer than that of the parent compound, leading to accumulation with repeated dosing or in renal impairment.
2. Hydrolysis: Ester hydrolysis, mediated by nonspecific esterases, yields meperidinic acid, an inactive metabolite.

Minor pathways include conjugation to form glucuronides. The formation clearance to norpethidine exhibits wide interindividual variability and can be influenced by enzyme inducers or inhibitors.

4.4. Excretion

Renal excretion is the final route of elimination for pethidine and its metabolites. Less than 5-10% of an administered dose is excreted unchanged in the urine. The majority is excreted as metabolites: meperidinic acid (inactive) and norpethidine (active). The renal clearance of pethidine is pH-dependent; acidification of urine increases the ionization of the drug and can enhance its renal excretion. The elimination half-life (t_1/2) of pethidine in adults with normal hepatic and renal function is approximately 3 to 5 hours. In contrast, the half-life of norpethidine is 15-40 hours, creating a significant risk for accumulation.

4.5. Dosing Considerations

Dosing must account for route, patient status, and the risk of norpethidine accumulation. A typical parenteral adult dose for acute pain is 50-100 mg IM/SC every 3-4 hours as needed. The equianalgesic potency ratio is roughly 1:10 compared to morphine (10 mg IM morphine ≈ 100 mg IM pethidine). Oral doses are approximately twice the parenteral dose due to first-pass effect (e.g., 100-200 mg). Crucially, dosing should be limited in duration, often to less than 48-72 hours for acute pain, to minimize norpethidine accumulation. For chronic pain, pethidine is generally contraindicated due to this risk.

5. Therapeutic Uses/Clinical Applications

The therapeutic applications of pethidine have narrowed considerably over time, with its use now largely confined to specific, short-term scenarios.

5.1. Approved Indications

• Management of Moderate to Severe Acute Pain: This remains the core indication, but its use is typically reserved for situations where specific benefits are perceived or other opioids are unsuitable. Examples include postoperative pain or pain associated with medical procedures, often where its shorter onset of action is utilized.
• Obstetric Analgesia: Historically a drug of choice for labor pain, pethidine is still used in some settings. Its potential to cause less neonatal respiratory depression compared to equipotent doses of morphine (though not compared to newer agents) and its atropine-like effect, which may counteract fetal bradycardia associated with opioids, have been cited as theoretical benefits. However, its use is declining in favor of epidural analgesia and other opioids like remifentanil.
• Preoperative Medication and Sedation: It may be used as part of pre-anesthetic medication for its sedative and anxiolytic effects.

5.2. Off-Label and Historical Uses

• Treatment of Rigors: Pethidine, particularly at low doses (e.g., 12.5-25 mg IV), is effective in terminating rigors associated with amphotericin B administration, blood transfusion reactions, or anesthesia. This effect is attributed to its action on the hypothalamus rather than pure opioid analgesia.
• Neuraxial Analgesia: Its local anesthetic properties allow for its use in epidural analgesia, providing both opioid and local anesthetic effects from a single agent.
• Pain in Acute Pancreatitis/Biliary Colic: The belief that pethidine causes less sphincter of Oddi spasm than morphine led to its historical preference in these conditions. However, evidence suggests it still increases biliary pressure, and its use is no longer strongly supported over other opioids.

It is critical to emphasize that pethidine is not recommended for the management of chronic pain due to the risk of norpethidine accumulation and neurotoxicity.

6. Adverse Effects

The adverse effect profile of pethidine includes common opioid-related effects and unique toxicities related to its metabolite.

6.1. Common Side Effects

These are extensions of its pharmacological action at mu-opioid receptors and are generally dose-dependent.

• CNS Effects: Sedation, dizziness, euphoria or dysphoria, and cognitive impairment.
• Gastrointestinal Effects: Nausea, vomiting (via stimulation of the CTZ), and constipation (via reduced gastrointestinal motility).
• Cardiovascular Effects: Peripheral vasodilation, orthostatic hypotension, and palpitations or tachycardia (due to its anticholinergic properties).
• Other: Dry mouth, sweating, and urinary retention.

6.2. Serious and Rare Adverse Reactions

• Respiratory Depression: Dose-dependent depression of brainstem respiratory centers, potentially leading to apnea, hypoxia, and death. Risk is increased with concomitant CNS depressants, in opioid-naïve patients, and in the elderly.
• Norpethidine Toxicity: Accumulation of norpethidine can lead to central nervous system excitation, manifesting as tremor, myoclonus (muscle twitching), hyperreflexia, and, ultimately, generalized tonic-clonic seizures. This risk escalates with repeated dosing, high doses, renal impairment, or use beyond 48-72 hours.
• Serotonin Syndrome: A potentially life-threatening condition characterized by the triad of autonomic hyperactivity (hyperthermia, tachycardia), neuromuscular abnormalities (hyperreflexia, clonus), and altered mental status. Pethidine’s serotonergic activity places patients at risk, especially when combined with other serotonergic drugs.
• Hypersensitivity Reactions: Rare instances of histamine release can cause pruritus, flushing, urticaria, and bronchospasm. True anaphylaxis is uncommon.
• Dependence and Abuse: Like all mu-opioid agonists, pethidine carries a high risk for the development of psychological dependence, physical dependence, and tolerance with prolonged use.

6.3. Warnings and Precautions

Pethidine carries a black box warning in many jurisdictions regarding its interaction with monoamine oxidase inhibitors (MAOIs). This interaction can precipitate a severe, sometimes fatal reaction characterized by excitability, hyperpyrexia, rigidity, hypotension or hypertension, and coma. Consequently, pethidine is contraindicated in patients currently taking or having recently taken MAOIs. Additional warnings highlight the risks of respiratory depression, abuse potential, and the danger of norpethidine accumulation.

7. Drug Interactions

Pethidine participates in numerous pharmacokinetic and pharmacodynamic interactions of clinical significance.

7.1. Major Pharmacodynamic Interactions

• Other CNS Depressants: Additive or synergistic depression of the CNS occurs with alcohol, benzodiazepines, barbiturates, other opioids, sedating antihistamines, and general anesthetics. This significantly increases the risk of profound sedation, respiratory depression, coma, and death.
• Monoamine Oxidase Inhibitors (MAOIs): This is an absolute contraindication. The interaction is complex and may involve inhibition of pethidine/norpethidine metabolism and exaggerated serotonergic effects, leading to the severe reaction described previously.
• Serotonergic Agents: Concurrent use with SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans, or other drugs that increase synaptic serotonin increases the risk of serotonin syndrome.
• Drugs with Anticholinergic Effects: Additive anticholinergic effects (tachycardia, urinary retention, ileus, confusion) may occur with tricyclic antidepressants, antihistamines, antipsychotics, and antispasmodics.

7.2. Major Pharmacokinetic Interactions

• CYP3A4 Inducers: Drugs such as rifampicin, carbamazepine, phenytoin, and St. John’s Wort may increase the metabolic clearance of pethidine, potentially reducing its analgesic efficacy and possibly altering the ratio of parent drug to norpethidine.
• CYP3A4 Inhibitors: Agents like ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice may decrease pethidine metabolism, leading to increased and prolonged opioid effects and an increased risk of adverse reactions.
• Drugs Affecting Urinary pH: Urinary acidifiers (e.g., ammonium chloride, high-dose ascorbic acid) may increase renal excretion of pethidine. Urinary alkalinizers may decrease its excretion, prolonging its effect.

7.3. Contraindications

• Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.
• Significant respiratory depression in unmonitored settings or in the absence of resuscitative equipment.
• Acute or severe bronchial asthma.
• Known or suspected gastrointestinal obstruction, including paralytic ileus.
• Hypersensitivity to pethidine or any component of the formulation.
• Established or suspected norpethidine toxicity (e.g., presence of myoclonus or seizures).

8. Special Considerations

The use of pethidine requires careful adjustment and monitoring in specific patient populations.

8.1. Pregnancy and Lactation

Pregnancy: Pethidine crosses the placenta. It is classified as Pregnancy Category C (US FDA) or its equivalent, indicating that risk cannot be ruled out. Use during labor may cause neonatal respiratory depression, altered neurological behavior (e.g., poor sucking reflex), and a lower Apgar score. Its use should be reserved for cases where the benefit justifies the potential fetal risk, typically for obstetric analgesia when other modalities are not available or appropriate.

Lactation: Pethidine and norpethidine are excreted in breast milk. The relative infant dose is considered low to moderate. However, due to the long half-life of norpethidine in neonates and its neurotoxic potential, repeated maternal dosing can lead to accumulation in the breastfed infant, causing sedation, poor feeding, and potentially CNS excitation. Short-term, single-dose use may be acceptable, but chronic use is contraindicated. Alternative opioids with shorter-acting metabolites are generally preferred.

8.2. Pediatric and Geriatric Considerations

Pediatrics: Pethidine can be used in children for acute pain, but caution is warranted. Dosing is weight-based (e.g., 0.5-1 mg/kg IM/SC, maximum single dose 100 mg). The risk of norpethidine accumulation and seizures exists in this population as well, limiting its use to short-term therapy. Its use for premedication or postoperative pain has declined in favor of safer alternatives.

Geriatrics: Older patients are particularly sensitive to the effects of pethidine. Age-related reductions in hepatic metabolism, renal function, and lean body mass, along with increased CNS sensitivity, lead to a higher peak effect, prolonged duration of action, and increased risk of adverse effects (confusion, falls, respiratory depression). Norpethidine accumulation occurs more readily due to reduced renal clearance. Dose reduction (often by 25-50%), increased dosing intervals, and strict avoidance of repeated dosing are mandatory. Many guidelines recommend avoiding pethidine in the elderly altogether.

8.3. Renal and Hepatic Impairment

Renal Impairment: This is a critical consideration. The clearance of both pethidine and, more importantly, norpethidine is significantly reduced. Norpethidine accumulation can occur rapidly, even after a few doses, leading to neurotoxicity. Pethidine is generally contraindicated in patients with moderate to severe renal impairment (e.g., creatinine clearance < 50 mL/min). If use is unavoidable in mild impairment, the dose must be drastically reduced, the frequency extended, and the duration limited to a single dose or a maximum of 24-48 hours, with close monitoring for myoclonus.

Hepatic Impairment: Reduced hepatic function impairs the N-demethylation and hydrolysis of pethidine, leading to decreased clearance of the parent drug and potentially altered metabolite formation. This can result in prolonged and exaggerated opioid effects. Dose reduction is necessary in patients with cirrhosis or severe hepatic disease. However, the primary concern remains norpethidine accumulation, which is more directly tied to renal excretion.

9. Summary/Key Points

The pharmacology of pethidine is defined by its status as a synthetic phenylpiperidine opioid with a complex and potentially hazardous profile.

• Pethidine is a mu-opioid receptor agonist with additional local anesthetic and mild anticholinergic properties.
• Its pharmacokinetics are dominated by hepatic metabolism via CYP3A4 to an active metabolite, norpethidine, which has a long half-life (15-40 hours) and significant neurotoxic and convulsant potential.
• Therapeutic use is now restricted primarily to short-term management of acute pain (e.g., postoperative, obstetric) due to the risk of norpethidine accumulation with repeated dosing. It is contraindicated in chronic pain.
• Major adverse effects include typical opioid effects (respiratory depression, sedation, nausea) and the unique risk of norpethidine-induced CNS excitation (tremor, myoclonus, seizures).
• A black box warning exists for a severe, potentially fatal interaction with monoamine oxidase inhibitors (MAOIs). It also poses a risk for serotonin syndrome with other serotonergic drugs.
• Pethidine is relatively contraindicated in the elderly and absolutely contraindicated in patients with significant renal impairment due to the high risk of norpethidine accumulation and toxicity.
• Clinical decision-making must weigh the specific, limited indications for pethidine against the availability of safer alternative opioid analgesics that lack a toxic, accumulating metabolite.

Clinical Pearls

1. The development of myoclonus in a patient receiving pethidine is a medical emergency signaling probable norpethidine toxicity and impending seizures; pethidine must be discontinued immediately.
2. When calculating equianalgesic doses in opioid rotation, remember the approximate 1:10 potency ratio (morphine:pethidine) but prioritize switching to an opioid without a toxic metabolite for long-term management.
3. In any patient with reduced renal function, regardless of indication, pethidine should be avoided. Its use should be documented with a clear clinical justification.
4. The treatment of pethidine-induced seizures involves standard anticonvulsants (e.g., benzodiazepines). Naloxone may reverse respiratory depression but is ineffective and may exacerbate the excitatory symptoms caused by norpethidine.
5. For rigors, a single, low IV dose (e.g., 12.5-25 mg) is often effective and carries a lower risk of cumulative toxicity compared to its use for analgesia.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.